News Articles on Neuromed Pharmaceuticals Ltd.

CombinatoRx and Neuromed Sign Merger Agreement

    - Merger to Create a Sustainable Biotechnology Company: Brings Together
    Significant Product Assets, Unique Discovery Capabilities and Fi
http://www.bioportfolio.com/news/CombinatoRx_and_Neuromed_Sign_Merger.html  - Thursday July 2 2009
Neuromed Announces Sale of U.S. Rights to Drug Candidate Exalgo(TM) (hydromorphone HCl) Extended-Release Tablets (CII) to Mallinckrodt
CONSHOHOCKEN, PA and VANCOUVER, BC, June 17 /PRNewswire/ - Neuromed Pharmaceuticals Ltd. announced today that its subsidiary Neuromed Development I
http://www.bioportfolio.com/news/Neuromed_Announces_Sale_of_U.S._Rights_to_Drug.html  - Wednesday June 17 2009
Neuromed Announces that Merck & Co., Inc. Terminates Research Collaboration and License Agreement for Compounds Targeting N-Type Calcium Channels
CONSHOHOCKEN, PA and VANCOUVER, BC, June 11 /PRNewswire/ - Neuromed Pharmaceuticals Ltd. announced today that it has received notification that Mer
http://www.bioportfolio.com/news/Neuromed_Announces_that_Merck_%26%2338%3B_Co.%2C_Inc..html  - Thursday June 11 2009
Neuromed Announces Exalgo(TM) (hydromorphone HCl) Extended-Release Tablets (CII) Meets Primary Efficacy Endpoint in Pivotal Phase 3 Trial
CONSHOHOCKEN, PA and VANCOUVER, BC, March 23 /PRNewswire/ - Neuromed Pharmaceuticals, Inc. today announced positive results of a pivotal phase 3 cl
http://www.bioportfolio.com/news/Neuromed_Announces_Exalgo%28TM%29_%28hydromorphone_HCl%29.html  - Monday March 23 2009